DUBLIN , April 1, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 25 th Annual Needham Healthcare Conference. Company management...
Jazz Pharmaceuticals (JAZZ) is a specialty biopharma company focused on neuroscience and oncology. JAZZ exhibits strong technical momentum. Shares are up nearly 50% over the past year. The stock maintains...
Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness
Seven presentations deliver new insights into zanidatamab's differentiated HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditionally...
1 Value Stock to Research Further and 2 We Ignore
3 Healthcare Stocks Walking a Fine Line
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales
– Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –